Kornimate/medical-research-clean huggingface dataset:
a clinical study for developing artificial intelligence(ai)-based clustering model for personalized medicine in acute respiratory failure

Conditions: Acute Respiratory Failure

Summary: we will prospectively collect clinical information to develop a clustering analysis model and confirm phenotype for patients with acute respiratory failure who admit to the intensive care unit and require oxygen supply beyond a high flow nasal cannula, and a control group without acute respiratory failure. and clinical characteristics and prognosis will be compared.


Eligibility criteria:
# inclusion criteria: - acute respiratory failure group among patients admitted to the internal medicine intensive care unit at samsung seoul hospital, if all of the following conditions are met: 1) age 18 or older 2) patients who require treatment with high flow nasal cannula (hfnc), non-invasive ventilation (niv (bipap or cpap)), or mechanical ventilation (mv) due to acute respiratory failure. - control group for comparative analysis, among patients admitted to the internal medicine intensive care unit at samsung seoul hospital who meet all of the following conditions, they are registered as a control group with the consent of the subjects and undergo the same research procedure. 1. age 18 or older 2. patients who do not require high flow nasal cannula (hfnc), non-invasive ventilation (niv (bipap or cpap)), or mechanical ventilation (mv) treatment * exclusion criteria: if any of the following criteria applies, you will not be permitted to participate in this clinical trial. 1. patients 48 hours after oxygen treatment (hfnc, niv (bipap or cpap), mv) 2. patients transferred from another hospital 3. patients with limitations in treatment

Keywords: phenotyping clustering analysis
bone anchored carriere motion appliance

Conditions: Malocclusion, Angle Class II

Summary: carriere motion appliance (cma) was designed to change a class ii molar relationship into a class i relationship by distalizing the whole posterior maxillary segment by means of class ii elastics and mandibular anchorage. to eliminate the adverse effects of cma with class ii elastics, we can use the cma to distalize the maxillary posterior segment with intra-arch anchorage using infrazygomatic miniscrews. the aim of this study is to evaluate skeletaly anchored cma for distalization of the maxillary buccal segment vs. conventionally anchored cma by comparing skeletal and dental measurements obtained from lateral cephalometric radiographs obtained prior to treatment (t0) and immediately after correction of class ii and remval of the appliance (t1).

thirty-two class ii malocclusion patients with age (11-16) years will be randomly allocated in the two groups: 1. conventional anchorage cma group (cag): conventional mandibular anchorage using essix retainer. 2. skeletal anchorage cma group (sag): anchorage by infra-zygomatic miniscrews. in the cag, class ii elastics will be attached from the maxillary canine to the mandibular first molar bilaterally with essix retainer in the lower arch as anchorage means. in the sag, closing coil spring will be attached from the maxillary canine to the infrazygomatic miniscrews bilaterally. for each patient, two lateral cephalograms will be obtained: one preoperatively and another after completion of distalization. model measurements will be made using the attached 3shape computer software.

Eligibility criteria:
inclusion criteria: 1. patients age (11-16) years. 2. full permanent dentition. 3. class ii malocclusion with at least an end-on class ii molar relationship bilaterally. exclusion criteria: 1. systemic conditions that may interfere with the treatment. 2. bad habits that might jeopardize the appliance. 3. transverse discrepancy. 4. previous orthodontic treatment.

Keywords: carriere motion appliance distalization skeletal anchorage infrazygomatic miniscrews
change trend of effluent eosinophil during peritoneal dialysis-related peritonitis

Conditions: Peritonitis

Summary: a multi-center prospective cohort study will be conducted to explore the change trend of eosinophil in peritoneal dialysis effluent during peritoneal dialysis-associated peritonitis, and to explore the relationship between eosinophil increase, peritonitis severity and antibiotic use. this study will provide evidence for routine eosinophil testing

a multi-center prospective cohort study will be conducted to explore the change trend of eosinophil in peritoneal dialysis effluent during peritoneal dialysis-associated peritonitis, and to explore the relationship between eosinophil increase, peritonitis severity and antibiotic use. in this study, 100 patients with peritoneal dialysis-associated peritonitis who meet the inclusion criteria will be selected. demographic data, laboratory variables, peritoneal fluid cytology and bacterial culture will be collected within 24 hours of peritonitis (day 1). peritoneal fluid cytology includes leukocyte classification and eosinophilic leukocyte count will be examined at day 3, 5, 7, 10, 14, 21, 30, 60 and 90 after peritonitis. all patients will be followed up for 90 days, and their peritonitis outcome will be recorded. the primary endpoint is the prevalence of eosinophil increase in peritoneal effluent, which is defined as \>100 eosinophils/mm\^3, or \>10% eosinophils of the total non-erythrocyte count. secondary end points are peritonitis outcome at month 1 and 3 including transfer to hemodialysis , death.

Eligibility criteria:
inclusion criteria: * diagnosed as peritoneal dialysis-related peritonitis; * age\> 14 years * maintenance peritoneal dialysis due to end-stage renal failure ≥3 months * use of lactate glucose dialysate exclusion criteria: * those who cannot be followed up regularly * reluctant to join this researcher

Keywords: peritonitis eosinophil peritoneal dialysis
developing methods for reconstructing electrical heart activity

Conditions: Heart Diseases; Cardiac Conduction Defect

Summary: non-invasive reconstruction of electrical heart activity can yield important scientific and clinical insights in cardiac rhythm disorders. in this study, the investigators aim at developing methods for reconstructing electrical heart activity non-invasively, and to use these methods to investigate cardiac rhythm disorders to answer clinical and scientific questions.


Eligibility criteria:
overall inclusion criteria: * 18 years or older * able to provide informed consent * conditions that might alter electrical conduction properties in the heart, including (but not limited to): brugada syndrome (bs), arrhythmogenic right ventricular cardiomyopathy (arvc), demonstrated ventricular arrhythmias (resuscitation, (non)sustained ventricular tachycardia, ventricular fibrillation) * implanted cardiac device, such as pacemaker or implantable cardioverter defibrillator additional inclusion criteria for group 1 (ct group): - existing medical indication for a cardiac ct scan unrelated to this research there are no additional inclusion criteria for group 2 (no-ct group). exclusion criteria: - known strong reaction against electrode attachment

Keywords: electrocardiography body surface potential mapping computational biology
sildenafil citrate for the management of asymmetrical intrauterine growth restriction

Conditions: Intrauterine Growth Restriction

Summary: intrauterine growth restriction (iugr) is defined as fetal abdominal circumference (ac) or estimated fetal weight (efw) \< 10th centile. in asymmetrical iugr the parameter classically affected is the abdominal circumference (ac). fetal growth restriction (fgr) complicates approximately 0.4% of pregnancies and severely increases the risk of perinatal morbidity and mortality. this is particularly due to premature delivery, both for fetal and for secondary maternal indications such as the development of pre-eclampsia. consequence of deficient uteroplacental blood flow, including iugr, pre-eclampsia, and placental abruption have been implicated in more than 50% of iatrogenic premature births. for this reason, the problem of severe iugr forms a substantial portion of the population that tertiary care centres care for. the effect of early-onset iugr is particularly significant: of those born alive, less than a third will survive their neonatal intensive care unit (nicu) stay without significant neurodevelopmental sequelae. survival rates for severely growth-restricted fetuses very remote from term (\<28 weeks' gestation) vary from 7% to 33%. as these early-onset iugr children are born very preterm, there are significant risks of neonatal mortality, major and minor morbidity, and long-term health sequelae. the use of ultrasound doppler waveform analysis in pregnancies complicated by iugr suggests compromised uteroplacental circulation and placental hypoperfusion. currently there are no specific evidence-based therapies for placental insufficiency and severe iugr. non-specific interventions include primarily lifestyle modifications, such as reducing or stopping work, stopping aerobic exercise, rest at home, and hospital admission for rest and surveillance. these interventions, which are not supported by evidence from randomized trials, are used in the belief that rest will enhance the uteroplacental circulation at the expense of that to the glutei and quadriceps muscles. there is evidence from ex vivo and animal models of growth restriction that the phosphodiesterase 5 inhibitor sildenafil citrate increases average birth weight and improves uteroplacental blood flow (umbilical artery, uterine artery).


Eligibility criteria:
inclusion criteria: * pregnant women ≥ 28 wk * diagnosed as asymmetrical intrauterine growth restriction exclusion criteria: * severe preeclampsia * fetus with reversed umbilical artery end diastolic flow. * symmetrical intrauterine growth restriction * diagnosed to have congenital anomalies. * diabetes mellitus with pregnancy. * patients with contraindication for the drugs given as gastric or duodenal ulcer, * twins pregnancy. * patients on antihypertensive or rheumatic heart disease * smokers.
electroporation therapy with bleomycin in treating patients with pancreatic cancer

Conditions: Pancreatic Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. electroporation therapy may enhance the ability of chemotherapy drugs to enter tumor cells. combining chemotherapy with electroporation therapy may kill more tumor cells. purpose: phase i trial to study the effectiveness of electroporation therapy and bleomycin in treating patients who have locally advanced pancreatic cancer.

objectives: i. determine the safety and surgical feasibility of electroporation therapy with bleomycin in patients with locally advanced pancreatic cancer. ii. determine the overall and progression-free survival of patients treated with this regimen. outline: patients receive bleomycin intratumorally during laparotomy. approximately 15 minutes after the intratumoral injection, patients receive bleomycin iv over 10 minutes. approximately 5 minutes after the iv injection, patients undergo electroporation therapy comprising electrical pulses directly to the pancreas and surrounding tissues. patients are followed weekly for 4-6 weeks and then every 2 months thereafter. projected accrual: a total of 15 patients will be accrued for this study within 12-18 months.

Eligibility criteria:
disease characteristics: diagnosis of adenocarcinoma of the pancreas unresectable disease by exploratory laparotomy involvement of the superior mesenteric artery or occlusion of the superior mesenteric vein-portal vein confluence no extrapancreatic metastases by ultrasound, ct scan, or laparotomy tumor must be accessible for direct injection of study drug and placement of electrode array patient characteristics: age: any age performance status: karnofsky 70-100% life expectancy: not specified hematopoietic: not specified hepatic: ast and alt no greater than 3 times upper limit of normal no impaired hepatic function renal: creatinine no greater than 1.5 mg/dl no impaired renal function cardiovascular: no impaired cardiac function pulmonary: no compromised pulmonary function no pulmonary condition that would potentially require the use of high fio2 levels other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception during and for 6 months after study no prior reaction to bleomycin no fever, infection, or other medical condition that would preclude study not at high risk for complications associated with abdominal surgery prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior lifetime cumulative dose of bleomycin greater than 400 u endocrine therapy: not specified radiotherapy: not specified surgery: see disease characteristics

Keywords: stage iii pancreatic cancer adenocarcinoma of the pancreas
molecular basis of langerhans and non-langerhans cell histiocytic neoplasms and castleman disease

Conditions: Castleman's Disease (CD); Langerhans Cell Histiocytosis (LCH); Non-Langerhans-Cell Histiocytosis

Summary: the purpose of this study is to use agnostic genomic evaluation using whole exome sequencing (wes) of a variety of rare hematologic diseases grouped under rare blood diseases and its variants to further elucidate the understanding of the chemistry of these disorders and identify potential actionable mutations that can be targeted with therapies in the context of clinical trials.

the study team will examine genetic changes, also known as mutations, in the dna of participants' blood, or if applicable, bone marrow specimen. these types of tests are increasingly used by doctors to improve the accuracy of diagnosis and make decisions during care. this study seeks to understand how many patients will benefit from this testing, and in what ways. the results of this portion of the study are placed in the individual's medical record and are communicated back to each participant.

Eligibility criteria:
inclusion criteria: * must have histopathologic confirmation of the particular rare hematologic disease. * diseases that will be considered as rare hematologic diseases for this study will include the following * langerhans cell histiocytosis (lch) * erdhiem chester disease (ecd) * rosai-dorfman disease (rdd) * miscellaneous histiocytic entities -indeterminate dendritic cell tumor, interdigitating dendritic cell sarcoma, follicular dendritic cell sarcoma, fibroblastic reticular cell tumor * unicentric castleman disease * multicentric castleman disease including tafro * follicular dendritic cell sarcoma (fdcs) * newly diagnosed treatment naïve patients as well as patients who received prior therapies (e.g. chemotherapy, targeted therapy, surgery, or radiation) will be included. -tissue specimens collected within the past 5 yearse will be considered acceptable for study inclusion will include the following * collected as part of the evaluation for diagnostic confirmation * tissue specimen or extracted dna (from blood sample) banked in irb approved tissue repositories and obtained within five years prior to the date of informed consent. -tissue samples are planned to be collectedfrom previously stored surgical specimens already being stored in pathology lab * consent to have germline testing performed in parallel to tumor testingg)patients willing to receive treatmen exclusion criteria: * life expectancy of less than 6months * patient unwilling to have germline testing performed on peripheral blood or buccal mucosa
taking care of her program in patients with stage iii or iv ovarian cancer and spouse caregivers

Conditions: Caregiver; Stage IIIA Ovarian Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Ovarian Cancer; Stage IV Ovarian Cancer

Summary: this pilot clinical trial studies the taking care of her program in patients with stage iii or iv ovarian cancer and spouse caregivers. this counseling program may equip the spouse caregiver with skills to support and nurture the patient through initial diagnosis and treatment. it may also help patients and spouse caregivers improve communication and coping skills.

primary objectives: i. test the feasibility of the study protocol, including recruitment and retention. ii. assess the short-term impact of the intervention on standardized measures of behavioral-emotional adjustment of spouse caregivers and diagnosed women on depressed mood, anxiety, quality of marital communication, perceived spousal support, and spouse caregivers' skills and self-confidence to manage the emotional toll of the illness on themselves and the ill partner. outline: patients and spouse caregivers complete the taking care of her program comprising 5 telephone-delivered intervention sessions over 45-60 minutes every 2 weeks. the intervention sessions are designed to provide training for spouse caregivers and patients to better manage the impact and emotional toll of recently diagnosed ovarian cancer, including its impact on their interpersonal communication and support about the cancer.

Eligibility criteria:
inclusion criteria: * spouses of women with diagnosed within the past 8 months with stage iii or iv ovarian cancer will be eligible to participate, as will the diagnosed wife/partner * spouses and patients must be married or cohabiting and in intimate relationship for at least 6 months * have english as one of their languages of choice (they can be multilingual) * have access to a telephone * have not been diagnosed with a prior cancer within the recent 5 years, except basal or squamous cell skin carcinoma * both heterosexual and same sex couples will be eligible exclusion criteria: * women diagnosed with stage iv ovarian cancer and who are hospice eligible * spouses/partners could not participate if the patient refused participation
comparison of patient perceived pain and satisfaction between lightweight and heavyweight mesh for laparoscopic inguinal hernia repair

Conditions: Inguinal Hernia

Summary: this study will be comparing the patients overall satisfaction of two different meshes used in laparoscopic inguinal hernia repairs.

this is a clinical trial comparing standard therapy in the use of either lightweight or heavy mesh for the repair of inguinal hernias. both types of these meshes have been approved for surgical correction but subjective comparisons of patient overall satisfaction and perceived outcomes have not been measured. the investigators intend to measure certain subjective data in the form of a questionnaire will be issued to the patient preoperatively, one week, one month, six months, and one year after the surgery there is no recent literature comparing subjective data between two meshes called ultra pro and surgi pro. the biological effects of these meshes have identical properties as far as the healing process and inflammation as well as the low rate of infection. the main difference is the material that these meshes are composed of. the ultra pro is made of prolene while the surgi pro is made of polypropylene. the risks are not increased anymore than that for normal surgical complications. they each have the same post operative risks including bleeding, infection and pain, but the investigators are investigating a possible subjective difference between these two separate meshes that are currently used.

Eligibility criteria:
inclusion criteria: * over the age of 18 * unilateral side to be repaired * no major abdominal surgery previously exclusion criteria: * under age 18 * bilateral repairs undertaken
cold snare piecemeal resection vs cold snare endoscopic mucosal resection

Conditions: Colon Cancer; Colon Polyp; Colon Adenoma; Serrated Polyp

Summary: the study will compare the use of cold snare piecemeal resection (cspr) vs cold endoscopic mucosal resection (cold emr). the study will include two cohorts: one cohort for conventional adenomas 10-19mm in size and one cohort for serrated lesions 10mm or larger.


Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age 2. presenting for a screening, surveillance, diagnostic, or therapeutic colonoscopy 3. found to have: * a sessile serrated lesion or hyperplastic polyp ≥ 10 mm during procedure (serrated cohort) or * a 10-19 mm conventional adenoma during procedure (adenoma cohort) 4. ability to provide informed consent exclusion criteria: 1. pedunculated or semi-pedunculated polyps (as defined by paris classification type ip or isp) 2. polyps confirmed to be anything other than: * sessile serrated lesion or hyperplastic polyp on histologic diagnosis (serrated cohort) or * conventional adenoma on histologic diagnosis (adenoma cohort) 3. patients with ulcerative colitis or crohn's disease 4. polyps with features suggestive of submucosal invasion 5. polyps that are not able to be removed endoscopically due to location (e.g. extending into appendiceal orifice or diverticulum) 6. patients with a known or suspected diagnosis of any of the following polyposis syndromes with known genetic mutations: * familial adenomatous polyposis syndrome * mutyh associated polyposis syndrome * juvenile polyposis syndrome * cowden's syndrome * peutz-jeghers syndrome 7. subjects whose colonoscopy procedure is not able to be completed due to bowel prep precluding polyp identification.

Keywords: polyp resection cold snare cold endoscopic mucosal resection (cold emr) cold snare piecemeal resection (cspr) colonoscopy
safety and tolerability of hemamax™ (rhuil-12) as radiation countermeasure

Conditions: Hematopoietic Syndrome Due to Acute Radiation Syndrome

Summary: this trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of hemamax in healthy male and female volunteers.

a randomized, placebo-controlled, double-blind study of hemamax to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single 12 μg subcutaneous dose of hemamax on 60 healthy subjects for 28 days after hemamax administration.

Eligibility criteria:
inclusion criteria: * male and female subjects, who have signed the informed consent form must meet all of the following criteria 1. 18 to 45 years of age 2. body mass index (bmi) \> 19 and \< 0 kg/m2 3. normal ecg, vital signs and laboratory test results 4. use of effective birth control method and abstinence from sex 5. negative pregnancy test and drug screen exclusion criteria: * subjects with any of the following characteristics will be considered ineligible: 1. history of clinically significant renal, hepatic pulmonary, cardiovascular, cerebrovascular, gastrointestinal, metabolic, hematological, endocrine, urological, immunological, neurologic or psychiatric disorders or connective tissue disease 2. positive for human immunodeficiency virus (hiv), hepatitis b, or surface antigen (hbsag) or hepatitis c antibody, tuberculosis (tb) 3. current drug or alcohol addiction 4. history of clinically significant allergy of any kind 5. prior use of il-12 or hemamax 6. use of any approved or investigational biologic agents or vaccinations of any kind in last 3 months

Keywords: hemamax, nm-il-12, hsars, safety